OncoQuest has entered into collaboration with Tesaro to conduct a proof-of-concept clinical trial evaluating the combination of oregovomab with ZEJULA (niraparib) in the recurrent ovarian cancer setting.
“We are excited to work with TESARO, an oncology-focused biopharmaceutical company, to evaluate the possible synergistic effects of combining ZEJULA with oregovomab in this important clinical setting,” stated Dr. Madi Madiyalakan, CEO of OncoQuest.
This will be the third Phase 1/2 clinical study evaluating oregovomab in combination with other drugs in the recurrent ovarian cancer setting. OncoQuest has two other trials in progress evaluating oregovomab in combination with nivolumab, a checkpoint inhibitor, and Hiltonol, an investigational TLR3 agonist, respectively.
OncoQuest recently presented positive interim clinical results for oregovomab in combination with standard of care carboplatin paclitaxel chemotherapy in the front line ovarian cancer setting. The final relapse free survival and overall survival data from the Phase 2 study is being compiled and the final clinical study report is expected to be presented to the regulatory authorities in the first half of 2018.
Under the terms of the collaboration, the trial will be sponsored by OncoQuest. TESARO will provide clinical supplies of niraparib and partial funding in support of the trial. Additional details of the collaboration were not disclosed. The trial is expected to begin in 2018.